Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
Europe
0
Canada
0
Australia
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
Annual Reports
NA
0
FDF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


| Molecular Weight | 877.0 g/mol |
|---|---|
| Molecular Formula | C47H64N4O12 |
| XLogP3 | 5.8 |
| Hydrogen Bond Donor Count | 6 |
| Hydrogen Bond Acceptor Count | 15 |
| Rotatable Bond Count | 6 |
| Exact Mass | 876.45207349 g/mol |
| Monoisotopic Mass | 876.45207349 g/mol |
| Topological Polar Surface Area | 217 A^2 |
| Heavy Atom Count | 63 |
| Formal Charge | 0 |
| Complexity | 1870 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 9 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 4 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 2 | |
|---|---|
| Drug Name | Priftin |
| PubMed Health | Rifapentine (By mouth) |
| Drug Classes | Antitubercular |
| Drug Label | PRIFTIN (rifapentine) for oral administration contains 150 mg of the active ingredient rifapentine per tablet. The 150 mg tablets also contain, as inactive ingredients: calcium stearate, disodium EDTA, FD&C Blue No. 2 aluminum lake, hydroxypropyl cel. |
| Active Ingredient | Rifapentine |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 150mg |
| Market Status | Prescription |
| Company | Sanofi Aventis Us |
| 2 of 2 | |
|---|---|
| Drug Name | Priftin |
| PubMed Health | Rifapentine (By mouth) |
| Drug Classes | Antitubercular |
| Drug Label | PRIFTIN (rifapentine) for oral administration contains 150 mg of the active ingredient rifapentine per tablet. The 150 mg tablets also contain, as inactive ingredients: calcium stearate, disodium EDTA, FD&C Blue No. 2 aluminum lake, hydroxypropyl cel. |
| Active Ingredient | Rifapentine |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 150mg |
| Market Status | Prescription |
| Company | Sanofi Aventis Us |
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39690
Submission : 2024-03-28
Status : Active
Type : II

GDUFA
DMF Review : Reviewed
Rev. Date : 2021-08-19
Pay. Date : 2021-07-08
DMF Number : 35961
Submission : 2021-06-30
Status : Active
Type : II
Date of Issue : 2025-11-12
Valid Till : 2028-11-10
Written Confirmation Number : WC-0079
Address of the Firm :

Date of Issue : 2022-08-16
Valid Till : 2025-07-15
Written Confirmation Number : WC-0042N
Address of the Firm :






FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Rifapentine is a Antibiotic drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Tuberculosis.
Lead Product(s): Rifapentine,Efavirenz,Emtricitabine,Tenofovir Disoproxil Fumarate
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Antibiotic
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 21, 2012
Lead Product(s) : Rifapentine,Efavirenz,Emtricitabine,Tenofovir Disoproxil Fumarate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Rifapentine is a Antibiotic drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Tuberculosis.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
September 21, 2012
Details:
Dolutegravir is a HIV type 1 integrase inhibitor, which is being evaluated in combination with daily rifapentine-moxifloxacin plus isoniazid and pyrazinamide regimen for HIV-associated tuberculosis.
Lead Product(s): Dolutegravir Sodium,Moxifloxacin,Rifapentine
Therapeutic Area: Infections and Infectious Diseases Brand Name: Tivicay
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: ViiV Healthcare
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 14, 2024

Lead Product(s) : Dolutegravir Sodium,Moxifloxacin,Rifapentine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : ViiV Healthcare
Deal Size : Inapplicable
Deal Type : Inapplicable
ACTG Launches Tuberculosis Drug Interaction Trial Among HIV Patients
Details : Dolutegravir is a HIV type 1 integrase inhibitor, which is being evaluated in combination with daily rifapentine-moxifloxacin plus isoniazid and pyrazinamide regimen for HIV-associated tuberculosis.
Product Name : Tivicay
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 14, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Dolutegravir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Tuberculosis-associated with HIV Infections.
Lead Product(s): Dolutegravir Sodium,Tenofovir Disoproxil Fumarate,Lamivudine,Rifapentine,Moxifloxacin,Isoniazid,Pyrazinamide
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: ViiV Healthcare | Viatris
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 30, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Dolutegravir Sodium,Tenofovir Disoproxil Fumarate,Lamivudine,Rifapentine,Moxifloxacin,Isoniazid,Pyrazinamide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : ViiV Healthcare | Viatris
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dolutegravir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Tuberculosis-associated with HIV Infections.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 30, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Through this agreement, Lupin will introduce two new formulations, a fixed-dose combination of Rifapentine + Isoniazid and Rifapentine 300 mg standalone tablets, at an affordable price for the treatment of tuberculosis.
Lead Product(s): Rifapentine,Isoniazid
Therapeutic Area: Infections and Infectious Diseases Brand Name: Rifapentine/Isoniazid-Generic
Study Phase: Approved FDFProduct Type: Antibiotic
Sponsor: Unitaid
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 07, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Rifapentine,Isoniazid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Unitaid
Deal Size : Undisclosed
Deal Type : Agreement
Details : Through this agreement, Lupin will introduce two new formulations, a fixed-dose combination of Rifapentine + Isoniazid and Rifapentine 300 mg standalone tablets, at an affordable price for the treatment of tuberculosis.
Product Name : Rifapentine/Isoniazid-Generic
Product Type : Antibiotic
Upfront Cash : Undisclosed
October 07, 2022

Details:
Rifapentine is a Antibiotic drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Tuberculosis.
Lead Product(s): Rifapentine,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Antibiotic
Sponsor: Gilead Sciences
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 16, 2020

Lead Product(s) : Rifapentine,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Gilead Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Rifapentine is a Antibiotic drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Tuberculosis.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
September 16, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Dolutegravir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of HIV Infections.
Lead Product(s): Dolutegravir Sodium,Isoniazid,Rifapentine,Pyridoxine Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: ViiV Healthcare
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 17, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Dolutegravir Sodium,Isoniazid,Rifapentine,Pyridoxine Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : ViiV Healthcare
Deal Size : Inapplicable
Deal Type : Inapplicable
Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals
Details : Dolutegravir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of HIV Infections.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 17, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Doravirine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Latent Tuberculosis.
Lead Product(s): Doravirine,Rifapentine,Isoniazid
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Walter K. Kraft
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 22, 2019

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Doravirine,Rifapentine,Isoniazid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Walter K. Kraft
Deal Size : Inapplicable
Deal Type : Inapplicable
Doravirine, Rifapentine and Isoniazid Interaction
Details : Doravirine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Latent Tuberculosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 22, 2019

Details:
Rifapentine is a Antibiotic drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Latent Tuberculosis.
Lead Product(s): Rifapentine,Isoniazid
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Antibiotic
Sponsor: University of Stellenbosch | Johns Hopkins University | Sanofi | University of Cape Town | Chris Hani Baragwanath Academic Hospital | Washington D.C. VA Medical Center
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 05, 2018

Lead Product(s) : Rifapentine,Isoniazid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : University of Stellenbosch | Johns Hopkins University | Sanofi | University of Cape Town | Chris Hani Baragwanath Academic Hospital | Washington D.C. VA Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Tuberculosis Clinical Trials Consortium Study 35
Details : Rifapentine is a Antibiotic drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Latent Tuberculosis.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
November 05, 2018

Details:
Rifapentine is a Antibiotic drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Tuberculosis.
Lead Product(s): Rifapentine,Midazolam
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Antibiotic
Sponsor: Sanofi | Centers for Disease Control and Prevention
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 14, 2010

Lead Product(s) : Rifapentine,Midazolam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Sanofi | Centers for Disease Control and Prevention
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers
Details : Rifapentine is a Antibiotic drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Tuberculosis.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
July 14, 2010

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
85
PharmaCompass offers a list of Rifapentine API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Rifapentine manufacturer or Rifapentine supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Rifapentine manufacturer or Rifapentine supplier.
PharmaCompass also assists you with knowing the Rifapentine API Price utilized in the formulation of products. Rifapentine API Price is not always fixed or binding as the Rifapentine Price is obtained through a variety of data sources. The Rifapentine Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A RPT manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of RPT, including repackagers and relabelers. The FDA regulates RPT manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. RPT API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of RPT manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A RPT supplier is an individual or a company that provides RPT active pharmaceutical ingredient (API) or RPT finished formulations upon request. The RPT suppliers may include RPT API manufacturers, exporters, distributors and traders.
click here to find a list of RPT suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A RPT DMF (Drug Master File) is a document detailing the whole manufacturing process of RPT active pharmaceutical ingredient (API) in detail. Different forms of RPT DMFs exist exist since differing nations have different regulations, such as RPT USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A RPT DMF submitted to regulatory agencies in the US is known as a USDMF. RPT USDMF includes data on RPT's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The RPT USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of RPT suppliers with USDMF on PharmaCompass.
A RPT written confirmation (RPT WC) is an official document issued by a regulatory agency to a RPT manufacturer, verifying that the manufacturing facility of a RPT active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting RPT APIs or RPT finished pharmaceutical products to another nation, regulatory agencies frequently require a RPT WC (written confirmation) as part of the regulatory process.
click here to find a list of RPT suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing RPT as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for RPT API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture RPT as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain RPT and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a RPT NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of RPT suppliers with NDC on PharmaCompass.
RPT Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of RPT GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right RPT GMP manufacturer or RPT GMP API supplier for your needs.
A RPT CoA (Certificate of Analysis) is a formal document that attests to RPT's compliance with RPT specifications and serves as a tool for batch-level quality control.
RPT CoA mostly includes findings from lab analyses of a specific batch. For each RPT CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
RPT may be tested according to a variety of international standards, such as European Pharmacopoeia (RPT EP), RPT JP (Japanese Pharmacopeia) and the US Pharmacopoeia (RPT USP).